Literature DB >> 3830722

Urinary pharmacokinetics of physostigmine in the rat.

S M Somani, A Boyer.   

Abstract

Urinary pharmacokinetics of 3H-Physostigmine (Phy) were studied in rat after an intramuscular administration of 650 micrograms/kg. Urine was collected at 0-1, 1-2, 2-4, 4-6, and 6-24 hr and every 24 hr for seven days. The rats were sacrificed by decapitation and the tissues were analyzed for radioactivity. Less than one percent (.87%) of the dose remained in tissues after the seventh day. Liver, followed by kidney, accounted for the highest activity compared to other tissues. The amounts of 3H-Phy and metabolites were determined by HPLC and the rapid decline of Phy in urine was observed. Most of the radioactivity found in the urine was due to metabolites (47% of dose in 24 hr) indicating extensive metabolism. The cumulative percent of radioactivity excreted in the urine was 30.3 +/- 12.6% in 6 hr, 44.4 +/- 13.1% in 24 hr which increased to 52.7 +/- 12.0% after seven days. Urinary elimination rate constant (Ku) of Phy was found to be .051 +/- .009 hr-1 indicating that the urinary elimination of Phy accounted for a minor part (2.5-4.%) of the systemic elimination.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830722     DOI: 10.1007/BF03189763

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Estimation of pharmacokinetic parameters of lithium from saliva and urine.

Authors:  U Groth; W Prellwitz; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

2.  An evaluation of drugs for improving memory in aged monkeys: implications for clinical trials in humans.

Authors:  R T Bartus; R L Dean; B Beer
Journal:  Psychopharmacol Bull       Date:  1983

3.  The protection of animals against organophosphate poisoning by pretreatment with a carbamate.

Authors:  J J Gordon; L Leadbeater; M P Maidment
Journal:  Toxicol Appl Pharmacol       Date:  1978-01       Impact factor: 4.219

4.  Effect of atropine and/or physostigmine on cerebral acetylcholine in rats poisoned with soman.

Authors:  L W Harris; W C Heyl; D L Stitcher; R D Moore
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

5.  Determination of physostigmine in plasma and brain by HPLC.

Authors:  S M Somani; A Khalique
Journal:  J Anal Toxicol       Date:  1985 Mar-Apr       Impact factor: 3.367

6.  Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis.

Authors:  S M Somani; K Chan; A Dehghan; T N Calvey
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

7.  Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration.

Authors:  S M Somani; A Khalique
Journal:  Fundam Appl Toxicol       Date:  1986-02

8.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Authors:  K L Davis; R C Mohs
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

9.  Physostigmine salicylate as an antidote.

Authors:  M Daunderer
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-12

10.  Hepatic and muscle clearance of physostigmine in the rat.

Authors:  L K Unni; S M Somani
Journal:  Drug Metab Dispos       Date:  1986 Mar-Apr       Impact factor: 3.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.